Christopher Sweeney

Christopher Sweeney led the landmark CHAARTED trial demonstrating that adding docetaxel to androgen deprivation therapy significantly improved overall survival in metastatic hormone-sensitive prostate cancer, particularly in high-volume disease. His work fundamentally changed the standard of care for mHSPC and established the high-volume versus low-volume stratification paradigm. He has subsequently contributed to ARASENS and other combination therapy trials. Sweeney's translational research examines genomic predictors of benefit from intensified therapy in mHSPC.